The purpose of this study is to determine the absorption, metabolism, excretion; and to evaluate the safety and tolerability of BMS-986435 in healthy male participants Participants will be admitted to the study site for 3 weeks.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
7
Specified dose on specified days
Local Institution - 0001
Madison, Wisconsin, United States
Maximum observed concentration (Cmax)
Time frame: Up to 45 days
Time to maximum observed concentration (Tmax)
Time frame: Up to 45 days
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))
Time frame: Up to 45 days
Metabolite profiling of BMS-986435 in plasma, urine, and feces
Time frame: Up to 45 days
Number of participants with adverse events (AEs)
Time frame: Up to 45 days
Number of participants with clinical laboratory abnormalities
Time frame: Up to 45 days
Number of participants with vital sign abnormalities
Time frame: Up to 45 days
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 45 days
Number of participants with physical examination abnormalities
Time frame: Up to 45 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.